US › Healthcare

TriSalus Life Sciences Inc. (TLSI)

US · Healthcare · Medical Devices

$3.63-6.92%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$11.4M

Revenue YoY

+1.7%

Net profit

$-9.2M

EPS

$-0.16

EPS estimate

$-0.15

Net margin

-80.5%

EPS came in at -0.16 against a street estimate of -0.15 — a miss of 6.7%.

Key statistics

Market cap

$246.3M

Forward P/E

0.0

P/B

47.00

Book value

$0.11

EPS (TTM)

$-1.18

52-week high

$7.95

52-week low

$2.20

50-day MA

$4.86

200-day MA

$4.58

Beta

0.47

Analyst view

Analysts rate TriSalus Life Sciences Inc. a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $10.40.

Shareholding

Insiders

33.96%

Institutions

35.73%

Largest institutional holders

Fund	Stake
First Light Asset Management, LLC	10.64%
BlackRock Inc	4.32%
Nantahala Capital Management, LLC	3.25%
Vanguard Capital Management, LLC	2.81%
HPM Partners LLC	2.60%
Geode Capital Management, LLC	1.93%
Gilder Gagnon Howe & CO LLC	1.38%
State Street Corp	0.99%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for TriSalus Life Sciences Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.